ZhouPYangX-LWangX-G, et al.
A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;
579:270–273. doi:10.1038/s41586-020-2012-7.
SavarinoABoelaertJRCassoneAMajoriGCaudaR.Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis. 2003;
3(11):722–727. doi:10.1016/S1473-3099(03)00806-5.
GaoJTianZYangX.Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;
14(1):72–73. doi:10.5582/bst.2020.01047.
6.
GautretPLagierJ-CParolaP, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print March 20, 2020]. Int J Antimicrob Agents. doi:10.1016/j.ijantimicag.2020.105949.
7.
YoungBEOngSWXKalimuddinS, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488–1494. doi:10.1001/jama.2020.3204.
8.
WuZMcGooganJM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. doi:10.1001/jama.2020.2648.
9.
YaoXYeFZhangM, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [published online ahead of print February 24, 2020]. Clin Infect Dis. doi:10.1093/cid/ciaa237.
MutaiWCMuigaiAWWaiyakiPKariukiS.Multi-drug resistant Salmonella enterica serovar Typhi isolates with reduced susceptibility to ciprofloxacin in Kenya. BMC Microbiol. 2018;
18(1):187. doi:10.1186/s12866-018-1332-3.